BioTuesdays

Beyond's analysis on BioTuesdays

• 2026-10-07 — AIM ImmunoTech highlights Ampligen’s potential to overcome immune resistance in pancreatic cancer, moving toward pivotal trial

Recent news mentioning BioTuesdays

• 2026-10-07 — AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays

Appears alongside

• AIM
• ImmunoTech

Browse the full archive →